Table 3 describes a series of RCTs, including double-blind and multinational designs, that have investigated the efficacy of various SGLT2 inhibitors in patients with HFpEF, often including those with or without T2DM and chronic kidney disease (CKD). Here, SLC5A2 is linked to chronic kidney disease.